Very Low-Dose Sublingual Ketamine for Borderline Personality Disorder and Treatment-Resistant Depression.
Mitchell B. Liester, Rachel Wilkenson, Barry Patterson, Bertrand Liang
Cureus April 1, 2024 DOI: 10.7759/cureus.57654 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | Woman with borderline personality disorder and treatment-resistant depression |
| Intervention | sublingual ketamine |
| Dose | very low-dose |
| Topics | Depression Esketamine Ketamine |
| Keywords | Ampa receptor Brain-derived neurotrophic factor Glutamate dysregulation Low dose ketamine Neuroplasticity enhancement Ketamine therapy Treatment-resistant mental health Neuroscience research Psychiatric medicine Personality disorders |
| Citations | 3 |
| Key findings | Very low-dose sublingual ketamine may be effective for treating borderline personality disorder and/or comorbid treatment-resistant depression. |
Abstract
Borderline personality disorder (BPD) and treatment-resistant depression (TRD) are common mental disorders that are challenging to treat. Ketamine is an N-methyl-D-aspartate receptor antagonist that has shown promise as a rapid-acting antidepressant when administered intravenously. BPD symptoms have also been demonstrated to improve with repeated intravenous administration of ketamine, and a single case report described improvement in BPD following the intranasal administration of esketamine. We present a case report of a woman with BPD and TRD who responded to treatment with very low-dose sublingual ketamine. Very low-dose sublingual ketamine may be effective for the treatment of psychiatric disorders such as BPD and/or comorbid TRD.
Comparable studies
Other case reports and case series on ketamine for depression, most cited first.